IL1RL2 and psoriasis 14, pustular: Spesolimab, a monoclonal antibody against IL-36R, has shown efficacy in early-phase trials, with ongoing phase II and III studies evaluating its potential in GPP (Thakur & Mahajan 2022; Ali et al. 2023; Bukhari et al. 2024).